Blood plasma treatment has limited effect for sickest COVID-19 patients
Treating critically ill COVID-19 patients with blood plasma from people who have fought off the disease has limited impact on patient outcomes.
Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
Treating critically ill COVID-19 patients with drugs typically used for arthritis may significantly improve survival, a landmark study has found.
Vaccine collaboration could overcome cold chain issues for RNA-based vaccines
Imperial vaccine researchers are collaborating with industry partners to develop RNA vaccines stable at temperatures up to 40C.
COVID-19 immunity lasts over 4 months, but antibody and T cells can “uncouple"
Majority carry neutralizing antibodies 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection, but antibody and T cell responses can "uncouple".
2
Coronavirus spread during dental procedures could be reduced with slower drills
Research from Imperial and King’s College London has found that careful operation of dental drills can minimise the aerosol spread of COVID-19.
1
Feature
Q&A: Cold chains, COVID-19 vaccines and reaching low-income countries
Many low-income countries lack the infrastructure to deliver vaccines effectively, so how can we ensure COVID-19 vaccines are accessible for all?
3
Video
New lab-on-chip infection test could give cheaper, faster portable diagnostics
A tiny new silicon-based lab-on-chip test could pave the way for cheap handheld infectious disease testing.
UK researchers to explore human challenge studies for COVID-19
Researchers are set to explore a human challenge study with the virus that causes COVID-19, the first such study anywhere in the world.
Bacteria-fighting cells in the airways boost infection risk from viruses
Having more bacteria-fighting immune cells in the nose and throat may explain why some people are more likely to be infected by respiratory viruses.
Cancer-causing HTLV-1 virus hijacks cellular machinery to establish infection
Scientists have used a cutting-edge visualisation technique to show how the human T-cell lymphotropic virus, type 1 (HTLV-1) infects immune cells.
